

# Premarket Approval (PMA) Submissions Workshop

Courtyard Irvine Spectrum | Irvine, CA

March 1-2, 2018

## March 1, 2018

**8:00 – 8:30 am Registration Check-In and Continental Breakfast**

**8:30 – 8:35 am Welcome and Introductions**

**8:35 – 9:30 am Beginning at the Beginning**

- When is a De Novo or PMA required
- PMA: what to expect
  - What are the standards of evidence
  - What are the standards of review
  - Will submission go to panel
  - How much will it cost
  - How long will it take to get approval

**9:30 – 10:15 am Development of a PMA Submission Strategy**

- Product definition
- Development of testing requirements and strategy
- Desired patient population
- Desired claims
- Early interactions with FDA
- Planning for product iterations

**10:15 – 10:30 am Break**

**10:30 – 11:30 am Mechanics of PMA Quality System Submission Development and Review**

*Bleta Vuniq, CDRH, FDA*

- Defining data requirements
- Required elements
- Presentation of information with clarity
- Expectations during review
- Best practices
- Manufacturing & Quality Systems

**11:30 – 12:15 pm During Submission Review**

- Interactions with the FDA
- When/How to expect questions
- Types of letters
- Timelines
- Day 100 meetings

### **Important Notice**

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



**AdvaMed**

Advanced Medical Technology Association  
Events & Education

- Labeling review

**12:15 – 1:15 pm**

**Lunch**

**1:15 – 2:00 pm**

**CDRH Ombudsman's Office – Roles & Responsibilities and the Appeals Process**  
*Abiy Desta, CDRH, FDA*

**2:00 – 2:45 pm**

**Preparation for Advisory Panels**  
*Rachael Roehrig, 3D Communications*

- When?
- Who are the panel members?
- Why have a panel meeting?
- Preparation for a panel meeting
- What to expect before, during, and after
- Best practices

**2:45 – 3:00 pm**

**Break**

**3:00 – 3:45 pm**

**BIMO Audits**  
*Sheena Green, CDRH, FDA*

- The purpose of a BIMO inspection
- When and how a BIMO inspection occurs
- Preventing findings and responding to findings
- Typical and atypical observations – cautionary tales from the field

**3:45 – 4:30 pm**

**Inspectional Activity**  
*Bleta Vuniq, CDRH, FDA*

- Pre-approval inspections
- How to prepare for an inspection

**4:30 – 5:30 pm**

**Networking Reception**

**March 2, 2018**

**8:30 – 9:00 am**

**Continental Breakfast**

**9:00 – 9:45 am**

**Conditions of Approval Studies**

- Criteria and objectives
- Early collaboration with FDA
- Reaching agreement
- Reporting outcomes
- 522 Studies

**Important Notice**

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



**AdvaMed**

Advanced Medical Technology Association  
Events & Education

<b>9:45 – 10:45 am</b>	<b>Dealing with the Unexpected</b> <i>Quynh Hoang, King &amp; Spaulding</i> <ul style="list-style-type: none"><li>• Clinical outcomes</li><li>• Animal test results</li><li>• Adverse panel recommendation</li></ul>
<b>10:45 – 11:00 am</b>	<b>Break</b>
<b>11:00 – 11:30 am</b>	<b>The Care and Feeding of Approved PMAs</b> <ul style="list-style-type: none"><li>• Periodic (“Annual”) Reports</li><li>• Supplemental Submissions</li></ul>
<b>11:30 – 12:00 pm</b>	<b>Real World Case Studies</b>
<b>12:00 pm</b>	<b>Adjournment</b>

**Important Notice**

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.